NCT03712969View on ClinicalTrials.gov

Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC

PHASE4CompletedINTERVENTIONAL

Enrollment

527

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

March 14, 2022

Study Completion Date

May 4, 2023

Conditions

Carcinoma, Non-Small-Cell LungChemotherapy, Adjuvant

Interventions

DRUG

Shenlingcao Oral Liquid

Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.

Trial Locations (1)

430030

Tongji Hospital, Wuhan

All Listed Sponsors

lead

West China Hospital

OTHER

NCT03712969 - Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC | Biotech Hunter | Biotech Hunter